To Explore (Discuss)the Relationship Between Platelet Aggregation Rate In The Early Period And Prognosis In Patients With Acute Coronary Syndrome

Objective:To explore the application of glycoprotein (GP)Ⅱb/Ⅲa receptor blockade tirofiban on the prognosis influence and the correlation between platclet aggregation rate(PAR)decreasing level and the prognosis in patients with acute coronary syndrome (ACS)based on conventional therapy of anticoagulation and antiplatelet.Methods:From March 2009 to September 2010,80ACS patients,(42 males,38females,age betwen34-68,mean age 59.07±9.29yeats old.50patients complicating with hypertension, 37patients complicating with diabetes,39patients had long-term smoking history) randomlgy divided into standard therapy group(n=42)and tirofiban group(n=38).The standard therapy group had been treated by Aspirin,Clopidogrel and Low Molecular Heparin.The tirofiban qroup had undergone the same treatment as the standard therapy group as well.Moreover,the tirofiban group was applicated by intravenous injection for loading dose 0.4ug/kg.min.for 30minutes,followed by 0.1 ug/kg.min and maintained for a mean of 24-48h.To observe the decreasing level of PAR and the standand time of two groups.To assess the change of Troponin I.Results:The PAR of tirofiban group had reached the standard level within 90 minutes after the treatment.The standard therapy group had reached the standard level within 2 hours after the treatment.The tirofiban group was found to be statistically significant.The peak troponin I levels and levels at 12-24-48 hours in the tirofiban group was markedly lower than those in the standard therapy group.The incidence of 24 hours and 30 days point events of cardiac and cerebral blood vessel occurred less frequently in the tirofiban group than those in the standard therapy group.There was no severe complications.few patients had gingival bleeding,subcutaneous ecchymosis, hematuria and epistaxis.There was no thrombocytopenia in two groups.There was no significant statistical difference in the incidence of bleeding complications between two groups.Conclusions:To apply glycoprotein(GP)Ⅱb/Ⅲa receptor blockade tirofiban in the early period can remarkably inhibit platelet aggregation,It's safe and effective in treating ACS.